Dipna Pharmachem Limited has announced a postal ballot notice for the appointment of M/s. Jay Pandya & Associates as Secretarial Auditor for the financial year 2025-26. The appointment, approved by the Board of Directors on April 22, 2026, is subject to shareholder approval through remote e-voting only, in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting and Appointment Details

The board meeting was held on April 22, 2026, at the company's registered office in Ahmedabad. The appointment of M/s. Jay Pandya & Associates was recommended by the Audit Committee and approved by the board in compliance with Regulation 24A of SEBI LODR Regulations and Section 204 of the Companies Act, 2013.

Shareholder Approval Through Remote E-Voting

The appointment requires shareholder approval through a postal ballot process using remote e-voting only. The company has engaged National Securities Depository Limited (NSDL) to facilitate the electronic voting process. The postal ballot notice is being sent electronically to members whose email addresses are registered with the Registrar and Share Transfer Agent (M/s. Bigshare Services Private Limited) and the depositories (NSDL and CDSL) as on the cut-off date of April 17, 2026.

Auditor Profile and Credentials

M/s. Jay Pandya & Associates is a practicing Company Secretaries firm with extensive experience in corporate law and securities regulations. The firm is peer-reviewed and eligible for appointment as Secretarial Auditors, with no disqualifications under SEBI Listing Regulations as per the SEBI Circular dated December 31, 2024. Mr. Jay Pandya, Proprietor of the firm, has been appointed as the Scrutinizer to conduct the postal ballot process in a fair and transparent manner.

The company confirmed that there are no relationships between the auditor firm and the company's directors, ensuring independence in the audit process. The Board and Audit Committee evaluated the firm's credentials, expertise, professional standing, and technical competence before recommending the appointment.

Regulatory Compliance and Filing

The company has filed the necessary documentation with BSE Limited under Regulation 30. The appointment is made to comply with the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 requirements. The resolution, if approved by the requisite majority of members, shall be deemed to have been passed on May 22, 2026, being the last date specified for e-voting.

Dipna Pharmachem Limited has fulfilled its quarterly regulatory obligations by submitting a compliance certificate under SEBI regulations for the quarter ended March 31, 2026. The submission, made on April 15, 2026, addresses the company's dematerialization activities during Q4FY26.

Regulatory Compliance Details

The certificate was submitted in accordance with Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. This regulation mandates listed companies to provide quarterly confirmations regarding their dematerialization processes through their designated Registrar and Share Transfer Agents.

Certificate Confirmation

Bigshare Services Private Limited, serving as the company's Registrar and Share Transfer Agent, issued the compliance certificate confirming specific operational details for the quarter. The RTA confirmed that no securities were received from depository participants for dematerialization during the period from December 31, 2025 to March 31, 2026.

The certificate further states that since no securities were processed for dematerialization, no physical certificates required mutilation and cancellation. Consequently, there was no need for substitution of depository names in the register of members as registered owners within the stipulated 15-day timeframe.

Corporate Governance

The submission was authorized by Keyur Dipakkumar Shah, Managing Director of Dipna Pharmachem Limited, bearing DIN 03167258. The document was digitally signed and submitted to BSE Limited, demonstrating the company's commitment to maintaining transparent corporate governance practices.

Company Information

Dipna Pharmachem Limited operates under CIN L24100GJ2011PLC066400 with its registered office located in Ahmedabad, Gujarat. The company maintains its regulatory compliance through systematic quarterly reporting to stock exchanges and regulatory authorities.